Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eliem Therapeutics Inc (NQ: ELYM ) 6.780 +0.150 (+2.26%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Eliem Therapeutics Inc < Previous 1 2 3 4 Next > 12 Health Care Stocks Moving In Thursday's Intraday Session February 23, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 20, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session February 17, 2023 Via Benzinga Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce February 10, 2023 Via Benzinga Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition February 09, 2023 From Eliem Therapeutics, Inc. Via GlobeNewswire Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study October 05, 2022 Via Benzinga Eliem Therapeutics: Q2 Earnings Insights August 15, 2022 Eliem Therapeutics (NASDAQ:ELYM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback August 02, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023 February 10, 2023 Via Benzinga Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 04, 2023 Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... Via Benzinga Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference November 30, 2022 From Eliem Therapeutics, Inc. Via GlobeNewswire Eliem Therapeutics Reports Third Quarter Financial and Business Highlights November 14, 2022 From Eliem Therapeutics, Inc. Via GlobeNewswire Eliem Therapeutics to Participate at Two Upcoming Investor Conferences November 08, 2022 From Eliem Therapeutics, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022 October 28, 2022 Upgrades Via Benzinga Eliem Therapeutics Provides Update on Pipeline Progress October 05, 2022 From Eliem Therapeutics, Inc. Via GlobeNewswire Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday September 23, 2022 Gainers Via Benzinga SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know August 16, 2022 SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $9.00 to $4.00. Shares of Eliem Therapeutics are trading down 2.08% over... Via Benzinga Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary August 02, 2022 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session August 02, 2022 Via Benzinga Recap of Monday's Biotech Catalysts - End of the Day Summary July 18, 2022 Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... Via Benzinga Eliem Announces Updated Development Plans For Its Delayed Depression Candidate July 18, 2022 In April, Eliem Therapeutics Inc (NASDAQ: ELYM) delayed ETX-155 into Phase 2a depression trials to determine the root cause of a lower-than-expected exposure observed in a Phase 1b study in... Via Benzinga This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday July 25, 2022 Gainers Via Benzinga SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know July 11, 2022 SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $13.00 to $9.00. Shares of Eliem Therapeutics are trading down 4.04% over... Via Benzinga The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives June 28, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug June 27, 2022 Eliem Therapeutics (NASDAQ: ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP). Via Benzinga 5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More June 21, 2022 Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 16, 2022 Via Benzinga 93 Biggest Movers From Yesterday June 14, 2022 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... Via Benzinga 5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard June 13, 2022 Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session June 01, 2022 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.